NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD
190.02
+0.39 (+0.21%)
The current stock price of ICLR is 190.02 USD. In the past month the price decreased by -5.8%. In the past year, price decreased by -41.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.2 | 202.33B | ||
DHR | DANAHER CORP | 27.74 | 149.40B | ||
A | AGILENT TECHNOLOGIES INC | 24.09 | 36.49B | ||
IQV | IQVIA HOLDINGS INC | 16.95 | 33.25B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 30.92 | 26.63B | ||
WAT | WATERS CORP | 31.79 | 22.41B | ||
WST | WEST PHARMACEUTICAL SERVICES | 34.42 | 16.83B | ||
ILMN | ILLUMINA INC | 36.22 | 14.07B | ||
RVTY | REVVITY INC | 22.89 | 13.65B | ||
AVTR | AVANTOR INC | 16.7 | 11.37B | ||
MEDP | MEDPACE HOLDINGS INC | 25.92 | 9.97B | ||
TECH | BIO-TECHNE CORP | 34.12 | 9.76B |
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 42,250 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
ICON PLC
South County Business Park, LEOPARDSTOWN, Dublin 18
DUBLIN DUBLIN 00000 IE
CEO: Steve Cutler
Employees: 42250
Company Website: https://www.iconplc.com/
Investor Relations: https://investor.iconplc.com/
Phone: 35312912000
The current stock price of ICLR is 190.02 USD. The price increased by 0.21% in the last trading session.
The exchange symbol of ICON PLC is ICLR and it is listed on the Nasdaq exchange.
ICLR stock is listed on the Nasdaq exchange.
27 analysts have analysed ICLR and the average price target is 260.16 USD. This implies a price increase of 36.91% is expected in the next year compared to the current price of 190.02. Check the ICON PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ICON PLC (ICLR) has a market capitalization of 15.69B USD. This makes ICLR a Large Cap stock.
ICON PLC (ICLR) currently has 42250 employees.
ICON PLC (ICLR) has a support level at 187.22 and a resistance level at 193.15. Check the full technical report for a detailed analysis of ICLR support and resistance levels.
The Revenue of ICON PLC (ICLR) is expected to grow by 1.37% in the next year. Check the estimates tab for more information on the ICLR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ICLR does not pay a dividend.
ICON PLC (ICLR) will report earnings on 2025-04-22, after the market close.
The PE ratio for ICON PLC (ICLR) is 13.57. This is based on the reported non-GAAP earnings per share of 14 and the current share price of 190.02 USD. Check the full fundamental report for a full analysis of the valuation metrics for ICLR.
The outstanding short interest for ICON PLC (ICLR) is 1.7% of its float. Check the ownership tab for more information on the ICLR short interest.
ChartMill assigns a fundamental rating of 5 / 10 to ICLR. ICLR has an average financial health and profitability rating.
Over the last trailing twelve months ICLR reported a non-GAAP Earnings per Share(EPS) of 14. The EPS increased by 9.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 9.56% | ||
ROA | 4.69% | ||
ROE | 8.31% | ||
Debt/Equity | 0.36 |
ChartMill assigns a Buy % Consensus number of 83% to ICLR. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of 3.36% and a revenue growth 1.37% for ICLR